{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fquadshot-news-podcast.simplecast.com%2Fepisodes%2F10282024-pola-NeEA8Z_9","width":444,"version":"1.0","type":"rich","title":"10.28.2024 - POLA","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/d4956b26-f7a3-4f47-a83d-9293649d65c8/ec08e780-4e06-4c01-8109-4e894d682296/qs_sqaure.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/340f7171-b1ea-4976-8709-a51baaea300d\" height=\"200\" width=\"100%\" title=\"10.28.2024 - POLA\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Check out this week's QuadCast as we discuss if PCV is better than TMZ for oligodendroglioma, discuss results of the hypo-FLAME trial for prostate cancer, highlight adjuvant RT for high risk bladder cancer in the BART trial, and more."}